779 related articles for article (PubMed ID: 25072648)
1. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
Hall LB; Zebardast N; Huang JJ; Adelman RA
J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
[TBL] [Abstract][Full Text] [Related]
4. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
5. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
Homer N; Grewal DS; Mirza RG; Lyon AT; Gill MK
Eye (Lond); 2015 Sep; 29(9):1152-5. PubMed ID: 26021870
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability.
Hata M; Oishi A; Tsujikawa A; Yamashiro K; Miyake M; Ooto S; Tamura H; Nakanishi H; Takahashi A; Yoshikawa M; Yoshimura N
Invest Ophthalmol Vis Sci; 2014 Nov; 55(12):7874-80. PubMed ID: 25395483
[TBL] [Abstract][Full Text] [Related]
7. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
[TBL] [Abstract][Full Text] [Related]
8. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
[TBL] [Abstract][Full Text] [Related]
9. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
[TBL] [Abstract][Full Text] [Related]
10. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab and aflibercept for the treatment of exudative age-related macular degeneration.
Selid PD; Jundt MC; Fortney AC; Beal JR
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(4):275-81. PubMed ID: 25037009
[TBL] [Abstract][Full Text] [Related]
12. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
Cho H; Shah CP; Weber M; Heier JS
Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
Peden MC; Suñer IJ; Hammer ME; Grizzard WS
Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
[TBL] [Abstract][Full Text] [Related]
15. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy.
Yannuzzi NA; Patel SN; Bhavsar KV; Sugiguchi F; Freund KB
Am J Ophthalmol; 2014 Aug; 158(2):319-327.e2. PubMed ID: 24814167
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
17. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.
Rasmussen A; Sander B; Larsen M; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H
Acta Ophthalmol; 2017 Mar; 95(2):128-132. PubMed ID: 27535819
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness of Intravitreal Aflibercept Injections in Patients who had Received 10 and More Ranibizumab Injections in Advance].
Lenk J; Matthé E; Pillunat LE; Sandner D
Klin Monbl Augenheilkd; 2016 Mar; 232(3):284-9. PubMed ID: 26562136
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration.
Beato J; Pedrosa AC; Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Melo A; Estrela-Silva S; Falcão-Reis F; Carneiro ÂM
Ophthalmic Res; 2016; 56(1):30-4. PubMed ID: 27046391
[TBL] [Abstract][Full Text] [Related]
20. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
